Biotron Financial Statements From 2010 to 2026
| BITRF Stock | USD 0.01 0.01 47.44% |
Check Biotron financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biotron's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biotron financial statements analysis is a perfect complement when working with Biotron Valuation or Volatility modules.
Biotron |
Biotron Limited Company Operating Margin Analysis
Biotron's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biotron Operating Margin | (1.78) % |
Most of Biotron's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotron Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Biotron Limited has an Operating Margin of -1.7832%. This is 94.92% lower than that of the Healthcare sector and 98.41% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 67.64% lower than that of the firm.
Biotron Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotron's current stock value. Our valuation model uses many indicators to compare Biotron value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotron competition to find correlations between indicators driving Biotron's intrinsic value. More Info.Biotron Limited is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotron's earnings, one of the primary drivers of an investment's value.About Biotron Financial Statements
Biotron stakeholders use historical fundamental indicators, such as Biotron's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biotron investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biotron's assets and liabilities are reflected in the revenues and expenses on Biotron's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biotron Limited. Please read more on our technical analysis and fundamental analysis pages.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Biotron operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Biotron Pink Sheet
Biotron financial ratios help investors to determine whether Biotron Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotron with respect to the benefits of owning Biotron security.